Subscribe to RSS
DOI: 10.1055/s-2005-871330
Chronic Inflammatory Demyelinating Polyneuropathy and Other Immune-Mediated Demyelinating Neuropathies
Publication History
Publication Date:
03 June 2005 (online)
ABSTRACT
The identification of specific disorders caused by immune-mediated attack on Schwann cells and myelin have both improved and confused our understanding and classification of chronic inflammatory and immune-mediated neuropathies. Some investigators consider all neuropathies that respond to immunosuppressive treatment as chronic inflammatory demyelinating polyneuropathy (CIDP), regardless of whether there is evidence for demyelination. Other investigators rely on a very strict definition of CIDP and do not include variations. The goal of this article is to clarify the spectrum of these disorders and provide a logical classification scheme that has clinical utility and yet allows for new information that might distinguish new variations. Therapeutic strategies are also discussed.
KEYWORDS
CIDP (chronic inflammatory demyelinating polyneuropathy) - myelin-associated glycoprotein - CANOMAD (chronic ataxic neuropathy, ophthalmoplegia, IgM paraproteinemia, cold agglutinins, and disialosyl antibodies) - paraprotein - MMN (multifocal motor neuropathy) - Lewis-Sumner syndrome - multifocal acquired demyelinating sensory and motor (neuropathy) - paraprotein - conduction block
REFERENCES
- 1 Dyck P J, Lais A C, Ohta M et al.. Chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 1975; 50 621-637
- 2 Haq R U, Pendlebury W W, Fries T J, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients. Muscle Nerve. 2003; 27 465-470
- 3 Sharma K R, Cross J, Farronay O, Ayyar D R, Shebert R T, Bradley W G. Demyelinating neuropathy in diabetes mellitus. Arch Neurol. 2002; 59 758-765
- 4 Gorson K C, Ropper A H, Adelman L S, Weinberg D H. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2000; 23 37-43
- 5 Krendel D A, Costigan D A, Hopkins L C. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol. 1995; 52 1053-1061
- 6 Ad Hoc Subcommittee of the American Academy of Neurology Task Force . Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology. 1991; 41 617-618
- 7 Saperstein D S, Katz J S, Amato A A, Barohn R J. The clinical spectrum of chronic acquired demyelinating polyneuropathy. Muscle Nerve. 2001; 24 311-324
- 8 Hughes R, Bensa S, Willison H et al.. Randomized controlled trial of intravenous immunoglobulin versus oral prednisone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001; 50 195-201
- 9 Magda P, Latov N, Brannagan III T H, Weimer L H, Chin R L, Sander H W. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol. 2003; 60 1755-1759
- 10 Gorson K G, Allam G, Ropper A H. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997; 48 321-328
- 11 Rotta F T, Sussman A T, Bradley W G, Ram Ayyar D, Sharma K R, Shebert R T. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2000; 173 129-139
- 12 Kaku D A, England J D, Sumner A J. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paraglobiside. Brain. 1994; 117 941-947
- 13 Katz J S, Saperstein D S, Gronseth G, Amato A A, Barohn R J. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000; 54 615-620
- 14 Willison H J, O’Leary C P, Veitch J et al.. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-diasialosyl IgM antibodies. Brain. 2001; 124 1968-1977
- 15 Willison H J, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002; 125 2591-2625
- 16 Lopate G, Choksi R, Pestronk A. Severe sensory ataxia and demyelination polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies. Muscle Nerve. 2002; 25 828-836
- 17 Soubrier M J, Dubost J J, Sauvezie B JM. POEMS syndrome: a study of 25 cases and a review of the literature. Am J Med. 1994; 97 543-553
- 18 Katz J S, Barohn R J, Kojan S et al.. Axonal multifocal motor neuropathy without conduction block or other features of demyelination. Neurology. 2002; 58 615-620
- 19 Parry G J, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve. 1988; 11 103-107
- 20 Pestronk A, Cornblath D R, Ilyas A A et al.. A treatable multifocal neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988; 24 73-78
- 21 Chad D A, Hammer K, Sargent J. Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome. Neurology. 1982; 32 958-964
- 22 Engel W K, Hopkins L C, Rosenberg B J. Fasciculating progressive muscular atrophy (F-PMA) remarkably responsive to antidysimmune treatment (ADIT): a possible clue to more ordinary ALS?. Neurology. 1985; 335(suppl 1b) 72
- 23 Freddo L, Yu R K, Latov N et al.. Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease. Neurology. 1986; 36 454-458
- 24 Roth G, Rohr J, Magistris M R, Oschner F. Motor neuropathy with proximal multifocal persistent block, fasciculations and myokymia. Evolution to tetraplegia. Eur Neurol. 1986; 25 416-423
- 25 Bouche P, Moulonguet A, Ben Younes-Chennnoufi A et al.. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry. 1995; 59 38-44
- 26 Comi G, Amadio S, Galardi G, Fazio R, Nemni R. Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 1994; 57(suppl) 35-37
- 27 Leger J-M, Younes-Chennoufi A B, Chassande B et al.. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry. 1994; 57(suppl) 46-49
- 28 Lange D J, Trojaberg W, Latov N et al.. Multifocal motor neuropathy with conduction block: is it a distinct clinical entity?. Neurology. 1992; 42 497-505
- 29 Oh S J, Kim D E, Kuruguolu H R. What is the best diagnostic index of conduction block and temporal dispersion?. Muscle Nerve. 1994; 17 489-493
- 30 Chaudhry V, Cornblath D R, Griffin J W et al.. Multifocal motor neuropathy: electrodiagnostic features. Muscle Nerve. 1994; 17 198-205
- 31 American Association of Electrodiagnostic Medicine . Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve. 1999; 22 S225-S229
- 32 Katz J S, Wolfe G I, Bryan W W, Jackson C E, Amato A A, Barohn R J. Electrophysiologic findings in multifocal motor neuropathy. Neurology. 1997; 48 700-707
- 33 Pakiam A S, Parry G J. Multifocal motor neuropathy without overt conduction block. Muscle Nerve. 1998; 21 243-245
- 34 Weimer L H, Grewal R P, Lange D J. Electrophysiologic abnormalities other than conduction block in multifocal motor neuropathy. Muscle Nerve. 1994; 9 A1089
- 35 Van den Berg L H, Franssen H, Van Doorn P A, Wokke J H. Intravenous immunoglobulin treatment in lower motor neuron disease associated with highly raised anti-GM1 antibodies. J Neurol Neurosurg Psychiatry. 1997; 63 674-677
- 36 Azulay J P, Blin O, Pouget J et al.. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo controlled study. Neurology. 1994; 44 429-432
- 37 Tsai C P, Lin K P, Liao K K et al.. Immunosuppressive treatment in lower motor neuron syndrome with autoantibodies against GM1. Eur Neurol. 1993; 33 446-449
- 38 Olney R K, Lewis R A, Putnam T D, Campellone Jr J V. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve. 2003; 27 117-121
- 39 Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology. 1992; 42 506-509
- 40 Kaji R, Oka N, Tsuji T et al.. Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol. 1993; 33 152-158
- 41 Kaji R, Kimura J. Facts and fallacies on anti-GM1 antibodies: physiology of motor neuropathies. Brain. 1999; 122 797-798
- 42 Ogawa-Goto K, Funamoto N, Abe T et al.. Different ceramide compositions of gangliosides between human motor and sensory nerves. J Neurochem. 1990; 55 1486-1493
- 43 Sheikh K A, Deerinck T J, Ellisman M H, Griffin J W. The distribution of ganglioside-like moieties in peripheral nerves. Brain. 1999; 122 449-460
- 44 Takigawa T, Yasuda H, Kikkawa R, Shigeta Y, Saida T, Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Neurol. 1995; 37 436-442
- 45 Waxman S G. Sodium channel blockade by antibodies: a new mechanism of neurological disease?. Ann Neurol. 1995; 37 421-423
- 46 Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology. 1997; 49 1289-1292
- 47 Van Schaik I N, Bossuyt P M, Brand A, Vermeulen M. Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis. Neurology. 1995; 45 1570-1577
- 48 Carpo M, Allaria S, Scarlato G, Nobile-Orazio E. Anti-GM1 IgM antibodies in multifocal motor neuropathy: slightly improved detection with covalink ELISA technique. Neurology. 1999; 53 2206-2207
- 49 Santoro M, Uncini A, Corbo M et al.. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol. 1992; 31 385-390
- 50 Van den Berg L H, Kerkhoff H, Oey P L et al.. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulin: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995; 59 248-252
- 51 Federico P, Zochodne D W, Hahn A F, Brown W F, Feasby T E. Multifocal motor neuropathy improved by IVIg. Randomized, double-blind, placebo-controlled study. Neurology. 2000; 55 1256-1262
- 52 Léger J-M, Chassande B, Musset L, Meininger V, Bouche P, Bauman N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind placebo-controlled study. Brain. 2001; 124 145-153
- 53 Van den Berg L H, Franssen H, Wokke J HJ. The long term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain. 1998; 121 421-428
- 54 Azulay J-Ph, Rihet P, Pouget J et al.. Long term follow up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry. 1997; 62 391-394
- 55 Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 1997; 63 765-769
- 56 Van den Berg-Vos R M, Franssen H, Wokke J HJ, Van den Berg L H. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain. 2002; 125 1875-1886
- 57 Nobile-Orazio E, Meucci N, Carpo M et al.. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry. 2002; 72 761-766
- 58 Van den Berg-Vos R M, Franssen H, Wokke J HJ, Van Es H V, Van den Berg L H. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin. Ann Neurol. 2000; 48 919-926
- 59 Van den Berg-Vos R M, Franssen H, Visser J et al.. Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment. J Neurol. 2002; 249 330-336
- 60 Pestronk A, Lopate G, Kornberg A J et al.. Distal lower motor neuron syndrome with high-titer serum IgM anti-GM1 antibodies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide. Neurology. 1994; 44 2027-2031
- 61 Pestronk A. Multifocal motor neuropathy: diagnosis and treatment. Neurology. 1998; 51(suppl 5) S22-S24
- 62 Lewis R A, Sumner A J, Brown M J, Asbury A K. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982; 32 958-962
- 63 Saperstein D S, Amato A A, Wolfe G I et al.. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve. 1999; 22 560-566
- 64 Van den Berg-Vos R M, Van den Berg L H, Franssen H et al.. Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity?. Neurology. 2000; 54 26-32
- 65 Oh S J, Claussen G C, Kim D S. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 1997; 2 362-369
- 66 Viala K, Renié L, Maisonobe T et al.. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain. 2004; 127 2010-2017
- 67 Nikhar N J, Lewis R A. Multifocal sensorimotor demyelinating neuropathy with persistent conduction block is distinct from multifocal motor neuropathy. Neurology. 1998; 50(suppl) A206
- 68 Parry G J. Are multifocal motor neuropathy and Lewis-Sumner syndrome distinct nosologic entities?. Muscle Nerve. 1999; 22 557-559
- 69 Lewis R A. Relationship of multifocal motor neuropathy and Lewis-Sumner syndrome. Muscle Nerve. 1999; 23 1738-1739
- 70 Barhon R J, Kissel J T, Warmolts J R, Mendell J R. Chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 1989; 46 878-884
Richard A LewisM.D.
Department of Neurology, Wayne State University School of Medicine
4201 Saint Antoine Street, Health Center 6E
Detroit, MI 48201-2153